Last reviewed · How we verify
CP-690,550 Ointment 1
CP-690,550 is a Janus kinase (JAK) inhibitor.
CP-690,550 is a Janus kinase (JAK) inhibitor. Used for Rheumatoid arthritis.
At a glance
| Generic name | CP-690,550 Ointment 1 |
|---|---|
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
JAK inhibitors block the activity of Janus kinases, enzymes that play a key role in signaling pathways involved in inflammation and immune responses. By inhibiting these enzymes, CP-690,550 reduces the production of pro-inflammatory cytokines and mediators, thereby exerting anti-inflammatory effects.
Approved indications
- Rheumatoid arthritis
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CP-690,550 Ointment 1 CI brief — competitive landscape report
- CP-690,550 Ointment 1 updates RSS · CI watch RSS
- Pfizer portfolio CI